Simultaneous CRISPR/Cas9 deletion of TRAC and CD7 prevents CAR-T cell fratricide and permits the safe use of allogeneic T cells by eliminating the potential for Graft-versus-Host Disease (GvHD) [3]. This evidence concerns the gene CD7 and graft versus host disease.